HUP9904026A3 - Use of sibutramine analogues to prevent the development of diabetes - Google Patents

Use of sibutramine analogues to prevent the development of diabetes

Info

Publication number
HUP9904026A3
HUP9904026A3 HU9904026A HUP9904026A HUP9904026A3 HU P9904026 A3 HUP9904026 A3 HU P9904026A3 HU 9904026 A HU9904026 A HU 9904026A HU P9904026 A HUP9904026 A HU P9904026A HU P9904026 A3 HUP9904026 A3 HU P9904026A3
Authority
HU
Hungary
Prior art keywords
diabetes
development
prevent
sibutramine
analogues
Prior art date
Application number
HU9904026A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of HUP9904026A2 publication Critical patent/HUP9904026A2/hu
Publication of HUP9904026A3 publication Critical patent/HUP9904026A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrotherapy Devices (AREA)
HU9904026A 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes HUP9904026A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process

Publications (2)

Publication Number Publication Date
HUP9904026A2 HUP9904026A2 (hu) 2000-05-28
HUP9904026A3 true HUP9904026A3 (en) 2000-07-28

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904026A HUP9904026A3 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Country Status (26)

Country Link
US (3) US6174925B1 (enExample)
EP (1) EP0927028A1 (enExample)
JP (1) JP2001503737A (enExample)
KR (1) KR20000048501A (enExample)
CN (1) CN1237905A (enExample)
AU (1) AU724488B2 (enExample)
BG (1) BG64473B1 (enExample)
BR (1) BR9711517A (enExample)
CA (1) CA2266401C (enExample)
CZ (1) CZ93699A3 (enExample)
GB (1) GB9619757D0 (enExample)
HR (1) HRP970505A2 (enExample)
HU (1) HUP9904026A3 (enExample)
ID (1) ID18320A (enExample)
IL (1) IL128850A (enExample)
MY (1) MY116150A (enExample)
NO (1) NO991358D0 (enExample)
NZ (1) NZ334580A (enExample)
PL (1) PL332305A1 (enExample)
RU (1) RU2245709C2 (enExample)
SK (1) SK31999A3 (enExample)
TR (1) TR199900618T2 (enExample)
TW (1) TW580385B (enExample)
UA (1) UA64726C2 (enExample)
WO (1) WO1998011884A1 (enExample)
ZA (1) ZA978450B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DK1093370T3 (da) * 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
AR018699A1 (es) 1999-06-01 2001-11-28 Procter & Gamble Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
PL1677792T3 (pl) * 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
CA2636324C (en) * 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
US20110024043A1 (en) 2009-07-02 2011-02-03 Dexcom, Inc. Continuous analyte sensors and methods of making same
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
CA2266401C (en) 2007-01-30
ID18320A (id) 1998-03-26
US6617360B1 (en) 2003-09-09
TW580385B (en) 2004-03-21
MY116150A (en) 2003-11-28
PL332305A1 (en) 1999-08-30
KR20000048501A (ko) 2000-07-25
JP2001503737A (ja) 2001-03-21
IL128850A0 (en) 2000-01-31
EP0927028A1 (en) 1999-07-07
BG103277A (en) 2000-01-31
NO991358L (no) 1999-03-19
NZ334580A (en) 2000-09-29
US20040077730A1 (en) 2004-04-22
TR199900618T2 (xx) 1999-06-21
NO991358D0 (no) 1999-03-19
WO1998011884A1 (en) 1998-03-26
AU724488B2 (en) 2000-09-21
RU2245709C2 (ru) 2005-02-10
SK31999A3 (en) 1999-12-10
GB9619757D0 (en) 1996-11-06
ZA978450B (en) 1999-03-19
AU4774097A (en) 1998-04-14
CZ93699A3 (cs) 1999-08-11
US6174925B1 (en) 2001-01-16
BG64473B1 (bg) 2005-04-30
HUP9904026A2 (hu) 2000-05-28
BR9711517A (pt) 1999-08-24
IL128850A (en) 2003-07-31
CA2266401A1 (en) 1998-03-26
HRP970505A2 (en) 1998-08-31
CN1237905A (zh) 1999-12-08
UA64726C2 (uk) 2004-03-15

Similar Documents

Publication Publication Date Title
HUP9904026A3 (en) Use of sibutramine analogues to prevent the development of diabetes
GB9713077D0 (en) Improvements relating to skin prickers
GB9525935D0 (en) Multithreaded processor
EP1008674A4 (en) PROCESSOR
GB9708512D0 (en) Improvements relating to skin prickers
HU9700927D0 (en) Fluorinated vitamine d3 analogues
AU136956S (en) Pedometer with game mode
ZA981419B (en) Arylsulfonamides and analogues
GB9727518D0 (en) Use
HU9700928D0 (en) Fluorinated vitamine d3 analogues
PL320923A1 (en) Graphite guide-rings
GB9404791D0 (en) Third body frictioning
ZA200304047B (en) Analogues of GLP-1.
KR0107809Y1 (en) Water-proof boot
GB2331742B (en) Monitoring the addition of a liquid agent to another liquid
GB9912318D0 (en) The use of staurosporine analogues for enhancing neutrophin activity
TW304478U (en) Pen structure of the finger-guessing game
SI0973511T1 (en) Use of sibutramine analogues to lower lipid levels
GB2332494B (en) Improvements relating to resilient mountings
TW327317U (en) Handle set with function of fastening
TW380680U (en) Improved structure of the revolving-horse-lamp
GB9709345D0 (en) The use of tramadol
TW307316U (en) Structure of shoesole with hard-and-soft features
TW391368U (en) Structure of elastic synthetic leather
TW323508U (en) Improved structure of functional hand

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees